Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Zoetis ( (ZTS) ) has shared an update.
On December 11, 2025, Zoetis announced a 6% increase in its quarterly dividend, declaring a dividend of $0.53 per share for the first quarter of 2026. This decision reflects the company’s commitment to delivering value to its shareholders and underscores its strong financial position in the animal health industry.
The most recent analyst rating on (ZTS) stock is a Buy with a $140.00 price target. To see the full list of analyst forecasts on Zoetis stock, see the ZTS Stock Forecast page.
Spark’s Take on ZTS Stock
According to Spark, TipRanks’ AI Analyst, ZTS is a Outperform.
Zoetis’s overall stock score is driven by its strong financial performance and strategic initiatives, despite current technical weaknesses. The company’s robust revenue growth and profitability, coupled with its commitment to innovation and shareholder value, position it well for future growth. However, bearish technical indicators and market challenges in specific segments temper the overall score.
To see Spark’s full report on ZTS stock, click here.
More about Zoetis
Zoetis is the world’s leading animal health company, dedicated to advancing care for animals through innovative solutions in predicting, preventing, detecting, and treating animal illnesses. With over 70 years of experience, the company supports veterinarians, pet owners, and livestock producers globally with a portfolio of medicines, vaccines, diagnostics, and technologies across more than 100 countries.
Average Trading Volume: 4,002,952
Technical Sentiment Signal: Sell
Current Market Cap: $51.01B
For an in-depth examination of ZTS stock, go to TipRanks’ Overview page.